Abstract

Introduction: Recent interest in understanding the cardiomyocyte cell cycle has been driven by potential therapeutic applications in cardiomyopathy. Despite advancements, the intricacies of cardiomyocyte mitosis, especially the breakdown of sarcomeres to enable daughter cardiomyocytes' division, remain largely unexplored. Hypothesis: This study investigates the role of Adducin in the disassembly of sarcomeres during cardiomyocyte mitosis, hypothesizing that Adducin serves as a crucial regulator in this process. Goals: Our objective is to elucidate the function of Adducin in sarcomere disassembly during the mitosis of mammalian cardiomyocytes and understand how this process is regulated. Methods: We examined the expression patterns of α/γ-Adducins, particularly in neonatal cardiomyocytes undergoing mitosis. Subsequently, we experimented with the overexpression of various α-Adducin splices and phosphorus in vitro and in vivo, with a keen interest in the phosphorylation effects of α-Adducin on sarcomere disassembly. Results: Here, we identify Adducin as a regulator of sarcomere disassembly during mammalian cardiomyocyte mitosis. α/γ-Adducins are selectively expressed in neonatal mitotic cardiomyocytes, and their levels decline precipitously thereafter. Cardiomyocyte-specific overexpression of various splice isoforms and phosphoforms of α-Adducin in vitro and in vivo identified Thr445/Thr480 phosphorylation of a short isoform of α-Adducin as a potent inducer of neonatal cardiomyocyte sarcomere disassembly. Additionally, co-overexpressing this α-Adducin variant with γ-Adducin in adult mice stabilizes the Adducin complex and maintains sarcomere disassembly, facilitated through interactions with α-Actinin. Conclusion: The study highlights Adducin, particularly α-Adducin phosphorylated at Thr445/Thr480, as a pivotal regulator of sarcomere disassembly during neonatal cardiomyocyte mitosis. This mechanism is essential for coordinating the cytoskeletal changes necessary for the mitotic process in cardiomyocytes, offering insights into potential therapeutic targets for cardiomyopathy.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.